|Videos|August 11, 2022
Clinical Study Data in Prostate Cancer Genomic Testing
Author(s)Stephen J. Freedland, MD
A key opinion leader provides an overview of study data investigating the clinical validity and clinical utility of the currently available genomic testing options in prostate cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants 510(k) clearance to OpenFlo urinary catheter
2
FDA grants fast track designation to VIR-5500 for mCRPC
3
Variation in PSMA PET Adoption for Prostate Cancer Care
4
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
5